Head-to-head evidence
rosuvastatin/ezetimibe vs vytorin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component) · full Atherosclerotic Cardiovascular Disease pipeline
rosuvastatin/ezetimibe
Developed by Yuhan Corporation
NCT02251847 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial using LDL cholesterol change, the standard measure for lipid-lowering therapies, as its primary endpoint, but results have not been posted. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: February 2029 · NCT06186037 (registry estimate)
vytorin
Developed by Organon
NCT00202878 · Phase 3 · completed
The trial randomly assigned 18,144 participants to Vytorin or simvastatin, used triple blinding, and included an active comparator. Its primary clinical endpoint occurred in 32.72% of the Vytorin group versus 34.67% of the simvastatin group; the difference was statistically significant (hazard ratio 0.936, 95% CI 0.887–0.988; p=0.016).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: rosuvastatin/ezetimibe's landscape · vytorin's landscape